Background: The addition of a FLT3 inhibitor (FLT3i) to standard chemotherapy to treat fit newly diagnosed (ND) patients with FLT3-mutated acute myeloid leukemia (AML) represents the standard of care resulting from clinical trial results. However, evidence regarding FLT3i adoption in routine clinical practice is still scarce. Methods: Clinical data are reported from 394 ND patients with FLT3-mutated AML enrolled in the retrospective observational Italian Cohort Study on FLT3-mutated patients with AML and treated with an upfront intensive regimen with (FLT3i group, n = 92) or without (CT group, n = 302) the addition of a FLT3i. Results: With a median follow-up time of 34.5 months, an effectiveness benefit obtained by FLT3i incorporation both in terms of overall survival (median, 34.9 in the FLT3i vs 12.7 months in the CT group, p <.01) and relapse-free survival (median, 18.9 in the FLT3i vs 7.6 months in the CT group, p =.01) was documented, with a higher composite complete remission rate (75.4% in the FLT3i vs 62.4% in the CT group, p =.052). FLT3i benefit seemed to be independent from the transplant rate. Conclusions: In conclusion, the benefit of FLT3i addition to upfront intensive treatment in newly diagnosed FLT3-mutated AML patients was confirmed in a large, real-life cohort study.
Nanni, J., Azzali, I., Papayannidis, C., Mule, A., Audisio, E., Martelli, M. P., Scappini, B., Chiusolo, P., Cambo, B., Candoni, A., Lunghi, M., Albano, F., Olivieri, A., Fracchiolla, N., Bernardi, M., Romani, C., Rigolin, G. M., Giannini, M. B., Bocchia, M., Todisco, E., Cilloni, D., Bochicchio, M. T., Ottaviani, E., Mattei, A., Zamagni, F., Valli, I., Volpi, R., Marconi, G., Petracci, E., Martinelli, G., Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life setting, <<CANCER>>, 2025; 131 (7): N/A-N/A. [doi:10.1002/cncr.35824] [https://hdl.handle.net/10807/311950]
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life setting
Chiusolo, Patrizia;
2025
Abstract
Background: The addition of a FLT3 inhibitor (FLT3i) to standard chemotherapy to treat fit newly diagnosed (ND) patients with FLT3-mutated acute myeloid leukemia (AML) represents the standard of care resulting from clinical trial results. However, evidence regarding FLT3i adoption in routine clinical practice is still scarce. Methods: Clinical data are reported from 394 ND patients with FLT3-mutated AML enrolled in the retrospective observational Italian Cohort Study on FLT3-mutated patients with AML and treated with an upfront intensive regimen with (FLT3i group, n = 92) or without (CT group, n = 302) the addition of a FLT3i. Results: With a median follow-up time of 34.5 months, an effectiveness benefit obtained by FLT3i incorporation both in terms of overall survival (median, 34.9 in the FLT3i vs 12.7 months in the CT group, p <.01) and relapse-free survival (median, 18.9 in the FLT3i vs 7.6 months in the CT group, p =.01) was documented, with a higher composite complete remission rate (75.4% in the FLT3i vs 62.4% in the CT group, p =.052). FLT3i benefit seemed to be independent from the transplant rate. Conclusions: In conclusion, the benefit of FLT3i addition to upfront intensive treatment in newly diagnosed FLT3-mutated AML patients was confirmed in a large, real-life cohort study.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
